What happens when millions of people simply stop wanting that second beer? In this episode of Beer In Front, I take a deep dive into the rapidly growing world of GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound—and explore how these drugs are reshaping the food and beverage industry. While most coverage focuses on weight loss, the bigger story may be changing consumer behavior. Research suggests GLP-1 medications don't just reduce appetite, they may also reduce cravings for alcohol, snacks, and other highly rewarding foods by affecting the brain's dopamine reward system.
Why GLP-1 users are drinking significantly less alcohol
New research showing dramatic reductions in alcohol cravings
How wine, beer, and spirits are being affected differently
Why bars and restaurants are seeing smaller checks and fewer repeat drink orders
The projected $30-$55 billion impact on the food and beverage industry
How grocery shopping habits are changing
The opportunities for premium alcohol, craft beverages, and non-alcoholic alternatives
Why GLP-1 medications could become an important tool in treating alcohol use disorder
What breweries, bars, restaurants, and food companies need to do to adapt
As adoption continues to grow and new oral versions of these medications reach the market, the effects on consumer spending and consumption habits may only accelerate.Whether you're in the beer business, restaurant industry, food manufacturing, or simply curious about how emerging health trends shape the economy, this episode explores one of the most important consumer shifts happening today.
StatisticSources 1 in 8 U.S. adults currently on a GLP-1 drug KFF Health Tracking Poll, Nov 2025 Up to 75% potential reduction in alcohol consumption Morgan Stanley 25% of GLP-1 users stopped drinking entirely Morgan Stanley 41% reduction in daily drinking (clinical trial) JAMA Psychiatry 2025 Wine down 52%, beer 43%, spirits 40% EY-Parthenon Survey 10% of adults = 50% of all alcohol sold U.S. alcohol consumption data $30–55B projected F&B revenue loss by 2030–34 J.P. Morgan Feb 2026 23% of households contain a GLP-1 user CNBC / industry data 2026 Dinner traffic down 6% among regular users Restaurant industry analysis, 2026
Podden och tillhörande omslagsbild på den här sidan tillhör
Dave Zalatoris. Innehållet i podden är skapat av Dave Zalatoris och inte av,
eller tillsammans med, Poddtoppen.
